Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.

Acta Neuropathol · 2026 · PMC13272220 · PMID 42301522

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A modest trend towards expanded GFAP expression was similarly observed, but did not reach statistical significance (Fig. 4 d, e).

also in 111,027 other papers

a nonsignificant trendno p-value reported

Despite reduced Aβ burden in aducanumab-treated cases, there was only a nonsignificant trend towards increased IBA1 coverage (Fig. 4 a, b).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.